April2025 is privigen in it still available?

Is Privigen still on the market in April 2025?
Privigen, the plasma‑derived immunoglobulin, is still sold in the United States and in most European Union countries. In the United Kingdom it is available only in a limited supply because the manufacturer is scaling back production in that region. [1]

Which countries can still get Privigen?
- United States: Full distribution remains active through major hospital pharmacies and specialty distributors.
- EU (Germany, France, Italy, Spain): Regular deliveries continue, and the drug is listed on national reimbursement lists in most member states.
- United Kingdom: Privigen is still listed in the NHS but only in a restricted quantity; patients may need to apply for special‑access programmes.

What could affect its availability?
- Supply chain constraints: A recent spike in plasma donations can limit the raw material supply.
- Manufacturing downtime: Planned maintenance at the UK production site may reduce output for a few months.
- Regulatory reviews: The FDA and EMA have requested additional post‑marketing data; approval of the requested studies could tighten availability temporarily.

Are there any supply shortages reported?
In March 2025, a small number of hospitals reported delayed shipments to the UK. No nationwide shortage has been announced, but the manufacturer warns of possible gaps during the next quarter.

What alternatives does a patient have?
- Gamunex‑C and Gammagard‑S: other plasma‑derived immunoglobulin products approved in the U.S. and EU.
- Biosimilar IgG: several biosimilar candidates are in late‑phase trials and may enter the market by 2027.
- Recombinant IgG: a recombinant immunoglobulin is under FDA review and could replace plasma‑derived options by 2028.

When do the key patents expire?
The original 10‑year patent covering the plasma‑derived purification process expires in 2029. A secondary patent protecting the formulation expires in 2031, which could allow biosimilar entry before that date.

Can biosimilars enter before patent expiry?
Yes. Under the U.S. FDA’s “biosimilar” pathway, a product can begin marketing approval before the original patent expires, provided it meets the regulatory standards for biosimilarity. Several companies are pursuing this route.

What about pricing and reimbursement?
Privigen’s average wholesale price in the U.S. is about $2,500 per 10 mL vial, with discounts of 15–20 % for bulk orders. In the EU, reimbursement rates vary by country but average €2,200 per vial. Pricing negotiations are ongoing for the UK due to the limited supply.

Key points for patients and clinicians
- Privigen remains accessible in most markets but watch for UK shortages.
- Keep an eye on biosimilar approvals that could lower costs in the next few years.
- If you need an alternative, discuss Gamunex‑C, Gammagard‑S, or upcoming recombinant options with your prescriber.

Sources
[1] https://www.drugpatentwatch.com